Advertisement
Financing › Details
ThromboGenics–Novartis: investment, 201709–201801 equity investment €10m by Novartis after termination of Jetrea agreement
Period | 2017-09-18 � 2018-01-26 | |
Money taker | ThromboGenics N.V. (Euronext Brussels: THR) | |
Today | Oxurion N.V. (Euronext Brussels: OXUR) | |
Group | Oxurion (Group) | |
Money source | Novartis AG (NYSE: NVS) | |
Group | Novartis (Group) | |
Product | Jetrea® | |
Product 2 | ophthalmic | |
ThromboGenics N.V.. (1/26/18). "Press Release: Novartis Pharma AG Holding 5.69% of ThromboGenics Equity Capital". Leuven.
Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 26 January 2018 from Novartis Pharma AG (‘Novartis’).
Novartis notified that, on 26 January 2018, the ThromboGenics shares controlled by Novartis are 2,177,226 shares, or 5.69% of the current 38,271,575 outstanding ThromboGenics shares.
ThromboGenics has issued 2,177,226 new ordinary shares to Novartis, increasing its number of outstanding shares to 38,271,575. This capital increase was approved at the Extra-ordinary Shareholders Meeting of 20 November 2017.
Novartis subscribed for newly issued shares at a price of €4.593 per share, corresponding with the average of the trading price calculated during the 30 days preceding approval on 20 November 2017.
On 26 January 2018, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:
Shareholder
number of securities
% of voting rights
Mr Thomas M. Clay and entities controlled by him
3,361,555
8.78%
Baron Philippe Vlerick and entities controlled by him
2,324,719
6.07%
Novartis Pharma AG
2,177,226
5.69%
For further information please contact:
ThromboGenics
Wouter Piepers, Global Head of Corp Coms & Investor relations
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/ Isabelle Andrews
Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics’ is currently evaluating THR-317, a PLGF inhibitor in a Phase I/IIa clinical study for the treatment of diabetic macular edema. Results are expected in Q1 2018. ThromboGenics’ late pre-clinical pipeline consists of THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos. THR-149 is expected to enter the clinic in the first half of 2018 and THR-687 around mid-2018. Further new drug candidates are currently being progressed for the treatment of diabetic eye disease and one of these is expected to enter development in 2018.
ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (in Europe and elsewhere).
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.
More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company’s Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
Record changed: 2018-09-15 |
Advertisement
More documents for Oxurion (Group)
- [1] Mogrify Ltd.. (11/2/21). "Press Release: Mogrify Appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor". Cambridge....
- [2] Oxurion N.V.. (5/17/21). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Executive Officer. Patrik De Haes M.D. Becomes Non-executive Chairman". Leuven & Boston, MA....
- [3] Oxurion N.V.. (10/13/20). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Financial Officer". Leuven & Boston, MA....
- [4] Bicycle Therapeutics plc. (8/8/19). "Press Release: Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update". Cambridge & Boston, MA....
- [5] Oxurion N.V.. (9/10/18). "Press Release: Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website". Leuven....
- [6] Bicycle Therapeutics Ltd.. (5/25/18). "Press Release: Bicycle Therapeutics Announces Clinical Milestone and Expands Collaboration with Thrombogenics". Cambridge & Boston, MA....
- [7] ThromboGenics N.V.. (3/15/18). "Press Release: ThromboGenics Business Update – FY 2017". Leuven....
- [8] ThromboGenics N.V.. (1/26/18). "Press Release: Novartis Pharma AG Holding 5.69% of ThromboGenics Equity Capital". Leuven....
- [9] ThromboGenics N.V.. (12/8/17). "Press Release: Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued Due to Slow Recruitment Rate". Leuven....
- [10] ThromboGenics N.V.. (11/8/17). "Press Release: ThromboGenics Strengthens Leadership Team". Leuven....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top